Given the patient's minimal ER positivity and the ambiguous benefits of endocrine therapy in such instances, the patient’s disease was treated as early-stage triple-negative breast cancer (TNBC), reflecting a tailored approach to management based on the comprehensive assessment of pathological findings and clinical context [22]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.